1. Home
  2. CDT vs DFLI Comparison

CDT vs DFLI Comparison

Compare CDT & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • DFLI
  • Stock Information
  • Founded
  • CDT 2019
  • DFLI 2020
  • Country
  • CDT United States
  • DFLI United States
  • Employees
  • CDT N/A
  • DFLI N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • DFLI Electronic Components
  • Sector
  • CDT Health Care
  • DFLI Technology
  • Exchange
  • CDT Nasdaq
  • DFLI Nasdaq
  • Market Cap
  • CDT 5.2M
  • DFLI 5.0M
  • IPO Year
  • CDT N/A
  • DFLI N/A
  • Fundamental
  • Price
  • CDT $0.54
  • DFLI $0.50
  • Analyst Decision
  • CDT
  • DFLI Strong Buy
  • Analyst Count
  • CDT 0
  • DFLI 4
  • Target Price
  • CDT N/A
  • DFLI $12.83
  • AVG Volume (30 Days)
  • CDT 7.4M
  • DFLI 252.3K
  • Earning Date
  • CDT 05-13-2025
  • DFLI 05-13-2025
  • Dividend Yield
  • CDT N/A
  • DFLI N/A
  • EPS Growth
  • CDT N/A
  • DFLI N/A
  • EPS
  • CDT N/A
  • DFLI N/A
  • Revenue
  • CDT N/A
  • DFLI $50,645,000.00
  • Revenue This Year
  • CDT N/A
  • DFLI $42.48
  • Revenue Next Year
  • CDT N/A
  • DFLI $42.95
  • P/E Ratio
  • CDT N/A
  • DFLI N/A
  • Revenue Growth
  • CDT N/A
  • DFLI N/A
  • 52 Week Low
  • CDT $0.51
  • DFLI $0.56
  • 52 Week High
  • CDT $350.00
  • DFLI $13.14
  • Technical
  • Relative Strength Index (RSI)
  • CDT 36.40
  • DFLI 18.84
  • Support Level
  • CDT $0.52
  • DFLI $0.60
  • Resistance Level
  • CDT $1.01
  • DFLI $0.67
  • Average True Range (ATR)
  • CDT 0.16
  • DFLI 0.09
  • MACD
  • CDT 0.02
  • DFLI 0.02
  • Stochastic Oscillator
  • CDT 3.43
  • DFLI 7.39

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a highly cost-effective storage solution.

Share on Social Networks: